GHK-Cu
Also known as copper tripeptide-1, GHK copper, prezatide copper, glycyl-L-histidyl-L-lysine copper
A three-amino-acid peptide bound to copper, used in skin care. Its human studies are topical; none injected GHK-Cu on its own or tested it systemically.
GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine bound to copper(II). Its human record is topical, small and mostly null on objective measures: every human study of GHK-Cu alone applied it to skin or scalp, two of the three indexed randomised trials found no difference from the comparator on objective measures, and no study has injected it on its own into a person. The one injection study found, an uncontrolled series, put a six-ingredient mixture containing it into scalp skin. It is listed here as in clinical trials because randomised human trials exist, but every one of them is topical, and none tested injection. FDA treats the two routes differently: non-injectable GHK-Cu is under evaluation for compounding, while for injection FDA records a possible immunogenicity risk.
What has been tested in people
Three indexed randomised trials, published between 1992 and 2006, all topical. In venous leg ulcers, a 0.4% copper peptide cream did no better than an inert vehicle in 86 evaluable patients. After CO2 laser resurfacing, 13 patients showed no difference in redness, wrinkles or skin quality on blinded assessment, although those using GHK-Cu rated their own skin better. In diabetic foot ulcers, a vehicle-controlled gel trial reported faster closure, but its abstract does not say how many patients took part, and several of its results are subgroups.
The facial studies cited in reviews of GHK-Cu are harder to check. A 2015 review, written by three authors at Skin Biology, a skin care company, describes several placebo-controlled studies in women around the age of 50. Of the four sources it cites, three are a conference presentation, a 2002 University of Pennsylvania document with no publication details and a book chapter, none of which could be retrieved. The fourth, which could, treated the thighs of 10 people for a month and had no placebo arm.
A newer trial of a GHK-Cu gel on its own is registered: NCT07437586, a randomised, vehicle-controlled study of a topical GHK-Cu gel on standardised acute skin wounds in healthy adults, sponsored by Hudson Biotech, with 60 participants estimated and no results posted. It is also topical.
Hair
No human trial of GHK-Cu alone on hair was found. The one placebo-controlled human hair trial found tested copper-free GHK combined with 5-aminolevulinic acid in men with pattern hair loss for six months. Hair count rose at both concentrations, but only the lower one differed from placebo, and hair length and thickness did not differ among the groups. It is not evidence about GHK-Cu. The other human reports are case series of mixtures: four patients given laser treatment, finasteride and several growth factors alongside a copper peptide, and a retrospective series of seven men tattooed with a solution of minoxidil, dutasteride and copper peptides. Neither can attribute anything to the copper peptide. An in-vitro hair study cited as GHK-Cu evidence tested AHK-Cu, a different tripeptide with alanine in place of glycine. A 1993 review describes follicle enlargement in fuzzy rats with a copper binding peptide it calls PC1031, without identifying it as GHK-Cu.
The gene-expression claim
The claim that GHK-Cu resets the genome, and the figure of at least 4,000 genes, come from the 2015 review above, which cites a 2014 paper by the same authors for it. That paper re-read three public expression profiles from two cell lines and counted genes whose mRNA level moved by half or more, putting the share at 32.1% in one place and 31.2% in another. That is a measurement of transcripts in cultured cells. It is not an outcome in skin, hair or any person.
Regulation
In the United States, FDA's 503A list updated on 14 May 2026 places GHK-Cu for non-injectable routes in category 1, under evaluation, and FDA plans to put it before its compounding advisory committee before the end of February 2027. The injectable nomination was withdrawn, and FDA's safety-risks page still lists it among withdrawn substances with its immunogenicity concern attached.
In Australia, a June 2026 joint statement from the Therapeutic Goods Administration and the Chief Medical Officer names GHK-Cu among unapproved peptide products that the TGA has not evaluated for safety, quality or effectiveness. The statement does not distinguish topical from injectable products. It was read by a person in a browser, because the TGA's site could not be reached from the research environment.
What the research shows
Each statement below is labelled with the strongest kind of study supporting it, and links to that study.
- Human randomised trialNo effect found / Moderate confidence
Applied topically as a 0.4% cream to venous stasis ulcers, a tripeptide copper complex did no better than an inert vehicle in a randomised, evaluator-blinded trial with 86 evaluable patients.
The trial compared three creams: 1% silver sulfadiazine, the 0.4% tripeptide copper complex and an inert vehicle. Silver sulfadiazine reduced ulcer size more than either of the others, and there was no difference between the copper cream and the vehicle.
Tested in humans under randomised, controlled conditions.
- Route: topical, on leg ulcers.
- The abstract names only a tripeptide copper complex. The National Library of Medicine indexes the study under glycyl-histidyl-lysine.
- Only the abstract was read. Treatment duration is not stated there.
- Evaluator-blinded, so the assessor but not necessarily the patient was blinded.
- Published in 1992 and not replicated in any indexed trial found.
- The abstract records non-governmental research support but names no sponsor.
- Human randomised trialMixed / Low confidence
Applied topically after CO2 laser resurfacing, GHK-Cu skin care products made no difference to redness, wrinkles or overall skin quality on blinded and computer assessment in a randomised trial with 13 completers, although patients using them rated their skin quality higher.
Patients were randomised to post-treatment regimens with or without GHK-Cu and followed for 12 weeks. Computer analysis and blinded evaluators found no difference between groups for earlier resolution of redness. Wrinkles and overall skin quality improved significantly in every patient, with no difference between groups. A patient questionnaire favoured GHK-Cu for overall skin quality (P = .04).
Tested in humans under randomised, controlled conditions.
- Route: topical, on facial skin after laser treatment.
- Thirteen patients completed the study.
- The abstract describes the comparator as a regimen without GHK-Cu, not as a matched vehicle.
- The only positive result is patient-reported, in patients who could not be blinded to a regimen difference as far as the abstract states.
- Only the abstract was read. It records non-governmental research support but names no sponsor.
- Human randomised trialSupportive / Low confidence
Applied topically as a gel to diabetic neuropathic plantar ulcers, GHK-Cu was reported to increase ulcer closure compared with vehicle in a randomised, evaluator-blinded, placebo-controlled multicentre trial.
The abstract reports 98.5% median closure of ulcer area with the gel against 60.8% with vehicle (p < 0.05), and fewer ulcer infections (7% against 34%) in ulcers treated immediately after debridement.
Tested in humans under randomised, controlled conditions.
- Route: topical, on foot ulcers.
- The sample size is not stated in the abstract, and the full text was not read, so the number of patients is unknown here.
- Several reported results are subgroup analyses, for ulcers larger than 100 square millimetres and for ulcers treated immediately after debridement.
- The abstract states that treatment had to start immediately after the initial debridement to get the best effect.
- Published in 1994, funding not stated in the abstract, and not replicated in any indexed trial found.
- It disagrees with the 1992 venous ulcer trial, which found no difference from vehicle. The wounds and formulations differ.
- Human case reportSupportive / Very low confidence
Applied topically to the thigh for one month, a copper-binding peptide cream increased procollagen staining in skin biopsies from baseline in 7 of 10 healthy volunteers, in a study with no placebo or vehicle arm.
Twenty volunteers each applied two different creams, one to each thigh. Procollagen staining rose from baseline in 4 of 10 with tretinoin, 5 of 10 with vitamin C, 5 of 10 with melatonin and 7 of 10 with the copper peptide cream.
One or a few individual cases. Cannot show whether an effect is general.
- Route: topical, on thigh skin, not the face.
- Ten people received the copper peptide cream, and there was no placebo or vehicle arm. Each result is a comparison with that person's own baseline.
- No statistical comparison between the creams is reported in the abstract.
- Procollagen staining in a biopsy is a surrogate marker, not a visible change in skin.
- A 2015 review by authors affiliated with a copper-peptide skin care company groups this study with placebo-controlled studies in women. The abstract describes healthy subjects, gives no sex, and has no placebo arm.
- Animal researchSupportive / Low confidence
Applied topically to open wounds in 18 New Zealand rabbits, a tripeptide-copper complex reduced unhealed wound area compared with no treatment over 21 days.
The 18 rabbits were divided into three groups: tripeptide-copper complex, zinc oxide and no treatment. Unhealed area was smaller with the copper complex than with no treatment on days 7, 14 and 21, and smaller than with zinc oxide on day 7.
Observed in animals. Animal results frequently fail to replicate in humans.
- Route: topical. New Zealand rabbits, not humans.
- The abstract names only a tripeptide-copper complex. The National Library of Medicine indexes the study under glycyl-histidyl-lysine.
- Eighteen animals across three groups. The abstract does not give the size of each group.
- The control group received no treatment rather than a vehicle, so the effect of applying any ointment is not separated from the effect of the copper complex.
- In-vitroSupportive / Low confidence
In a cultured keratinocyte model, GHK-Cu was not cytotoxic and did not significantly change skin-irritation biomarkers, while copper chloride and copper acetate raised them.
The study compared the copper peptide with two inorganic copper salts. After 24 hours the salts raised IL-1 alpha, IL-8 and other irritation markers without reducing cell viability; GHK-Cu changed none of them significantly, and the authors conclude it has a low potential to irritate skin.
Observed in cells or tissue outside a living organism.
- Route: in vitro, as a model of topical exposure.
- Skin cells in culture, not skin in a person.
- This says nothing about injection.
- Only the abstract was read.
- Mechanistic reasoningInsufficient evidence / Moderate confidence
No study in which GHK-Cu on its own was injected into people, or given by any systemic route, was found, and FDA states that there are limited data in humans to inform safety-related considerations for the injectable route.
Every human study of GHK-Cu alone applied it to skin or scalp. One uncontrolled study injected a six-ingredient mixture that included copper tripeptide-1 into the scalp skin of 1000 patients, which cannot isolate GHK-Cu. FDA's own safety text for compounded injectable GHK-Cu says human data to inform its safety are limited.
A plausible biological explanation, not a measured outcome.
- Route: systemic. The absence of injection studies is the result of searches of PubMed and ClinicalTrials.gov on 7 October 2026, not a statement FDA makes in those words.
- An absence of studies is not evidence of safety or of harm. It means the question has not been tested in people.
- Topical findings elsewhere on this page say nothing about what happens when the substance is injected.
- The mixture study was open-label and single-arm, combined copper tripeptide-1 with thymosin beta-4 and four growth factors, delivered it into the skin rather than systemically, and reports tolerability only as "Treatment was well tolerated."
- One retrospective series of seven men delivered a solution of minoxidil, dutasteride and unidentified copper peptides into the scalp by tattooing needle. That is delivery into the skin, not systemic dosing, and the copper peptide is not identified as GHK-Cu.
- Mechanistic reasoningInsufficient evidence / Low confidence
In Connectivity Map expression profiles from two cell lines, GHK was associated with a change of 50% or more in the mRNA level of about a third of the genes measured.
The authors re-analysed three public gene expression profiles, two from one cell line and one from another, and counted genes whose expression rose or fell by at least half. The paper gives the share as 32.1% in one place and 31.2% in another. This is a count of transcripts in cultured cells, not an effect on skin, hair or any person.
A plausible biological explanation, not a measured outcome.
- Route: in vitro, and in silico. Cultured cell lines, not skin.
- Three profiles from two cell lines, with no stated replication.
- The paper reports two different percentages for the same quantity, 32.1% and 31.2%.
- The authors are affiliated with Skin Biology, a company whose research and development department is given as their address.
- The figure of at least 4,000 genes that circulates online comes from the same authors' 2015 review, which cites this paper for it. This paper itself gives percentages, not that number.
- A change in mRNA level is not a change in protein, tissue or outcome.
- Mechanistic reasoningSupportive / Low confidence
A Connectivity Map analysis identified GHK as a compound predicted to reverse a gene-expression signature of emphysema-related lung destruction, and in cultured fibroblasts from COPD lungs it restored collagen contraction and remodelling.
The investigators profiled lung tissue from smokers with COPD, identified GHK computationally as a compound that could reverse the expression pattern linked to tissue destruction, then tested it in cultured human fibroblasts, where it reproduced TGF-beta-like expression patterns. In fibroblasts derived from COPD lungs it restored collagen contraction and remodelling.
A plausible biological explanation, not a measured outcome.
- Route: in vitro. Fibroblasts in culture, studied for COPD, not skin.
- The abstract refers to GHK and does not state whether copper was present.
- Only the abstract was read.
- A predicted reversal of a gene signature is a hypothesis, not a demonstrated effect in tissue.
Reported and theoretical risks
- Mechanismtheoretical
Compounded injectable GHK-Cu may provoke an immune response
FDA states that compounded injectable drugs containing GHK-Cu may pose a risk of immunogenicity because of the potential for aggregation and peptide-related impurities. This is a regulator's reasoned concern about the injected product, not a harm observed in a study.
- Mechanismunknown
There is no human safety record for injection
No study of GHK-Cu on its own given by injection to people was found; the one injection study found used a six-ingredient mixture and reports tolerability in a single sentence. FDA states that there are limited data in humans to inform safety-related considerations. The abstracts of the topical GHK-Cu trials report no adverse-event data, and topical studies could not inform the safety of injection in any case.
Regulatory status
Status differs by country and changes over time. Each entry is dated and sourced.
USFDAunclear
For non-injectable routes, GHK-Cu is in 503A category 1, bulk drug substances under evaluation for use in compounding. It was removed from category 1 on 22 April 2026 after the nominations were withdrawn, then restored after one nominator clarified on 5 May 2026 that it had meant to withdraw only the injectable route. Category 1 means under evaluation, not approved for compounding. This document does not state whether any approved drug contains GHK-Cu.
As of 14 May 2026. Source
USFDAunclear
For injectable routes, GHK-Cu is listed on FDA's safety-risks page among substances previously in category 2 whose nominations were withdrawn. FDA's stated concern remains on the page: compounded injectable GHK-Cu may pose a risk of immunogenicity due to aggregation and peptide-related impurities, and human data on safety are limited. A withdrawn nomination is neither an approval nor a ban.
As of 22 April 2026. Source
USFDAunclear
FDA has said it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 on whether GHK-Cu should be added to the 503A bulks list. GHK-Cu is named on the committee's future meeting page, whose time and location were still to be scheduled, and no briefing document had been published.
As of 15 April 2026. Source
AUTGAnot approved
In a joint statement with Australia's Chief Medical Officer of 19 June 2026, the TGA names GHK-Cu among unapproved peptide products that are not included in the Australian Register of Therapeutic Goods and have not been evaluated by the TGA for safety, quality or effectiveness. The statement was read in a browser by a person on 4 October 2026, because the TGA's website could not be reached from the environment used to research this page.
As of 19 June 2026. Source
Research and analysis
Sources
- 1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. View source(open access)
- 2. Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. Journal of Cosmetic and Laser Therapy. 2018. PubMed 29482481
- 3. Bishop JB et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. Journal of Vascular Surgery. 1992. PubMed 1495150
- 4. Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery. 2006. PubMed 16847171
- 5. Mulder GD et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair and Regeneration. 1994. PubMed 17147644
- 6. Abdulghani AA et al. Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with tretinoin on the ultrastructure of normal skin: a pilot clinical, histologic, and ultrastructural study. Disease Management and Clinical Outcomes. 1998. View source
- 7. Cangul IT et al. Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits. Veterinary Dermatology. 2006. PubMed 17083573
- 8. Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. BioMed Research International. 2014. PubMed 25302294(open access)
- 9. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015. PubMed 26236730(open access)
- 10. Campbell JD et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine. 2012. PubMed 22937864(open access)
- 11. Li H et al. Selected Biomarkers Revealed Potential Skin Toxicity Caused by Certain Copper Compounds. Scientific Reports. 2016. PubMed 27892491(open access)
- 12. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, updated May 14, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 13. Meeting of the Pharmacy Compounding Advisory Committee (to be scheduled before the end of February 2027). U.S. Food and Drug Administration. 2026. View source(open access)
- 14. Concerns regarding the public health risks associated with unapproved peptide products. Therapeutic Goods Administration. 2026. View source(open access)